Latest Updates
-
Deepika Padukone Wears ₹90,000 Gold Kurta Set As Ranveer Singh, Daughter Dua Twin For Baby Devi’s Name Reveal -
Women, Menopause And Bone Health: Doctor Explains Why Osteoporosis Risk Rises After 40 -
Can Breast Cancer Be Detected Before Symptoms Appear? A Doctor Explains The Role Of Screening -
Papankusha Ekadashi 2026: October 21 Or 22? Know The Correct Date, Tithi And Significance -
OTT Releases This Week (October 19–25): New Movies And Series On Netflix, Prime Video, JioHotstar And Zee5 -
Police Commemoration Day 2026: Know The History, Significance And Programmes Planned Across India This Year -
Deepika Padukone And Ranveer Singh Announce Second Daughter’s Name On Dussehra, Share Family Photo -
Who Was Karthik Sabesh? Tamil Actor Passes Away At 37, Days After Uncle And Composer Deva’s Death -
Who Is Ravleen Varghese? Meet The First Malayali Model To Walk The Victoria’s Secret Runway -
World Osteoporosis Day 2026: A Minor Fall, A Major Fracture — Doctor On Why Older Adults Should Be Careful
Half Of Cancer Drugs Approved In UK Show No Survival Benefits
Cancer drugs in UK shown to have no survival benefits whatsoever. Read to find out!
Over half of cancer drugs approved for use in the UK in recent years are not proven to extend life, according to a study. Even where drugs did show survival gains over existing treatments, these were often marginal, the results published in the British Medical Journal (BMJ) show.
Many of the drugs were approved on the basis of indirect ('surrogate') measures that do not always reliably predict whether a patient will live longer or feel better, raising serious questions about the current standards of drug regulation, researchers said.

"When expensive drugs that lack clinically meaningful benefits are approved and paid for within publicly funded healthcare systems, individual patients can be harmed, important societal resources wasted, and the delivery of equitable and affordable care undermined," they said.
The research team based at King's College London and the London School of Economics in the UK analysed reports on cancer approvals by the European Medicines Agency (EMA) from 2009 to 2013. Of 68 cancer indications approved during this period, 57 per cent (39) came onto the market on the basis of a surrogate endpoint and without evidence that they extended survival or improved the quality of patients' lives, researchers said.
After a median of five years on the market, only an additional eight drug indications had shown survival or quality of life gains, they said. Out of 68 cancer indications approved by the EMA, and with a median five years follow-up, only 35 (51 per cent) had shown a survival or quality of life gain over existing treatments or placebo. For the remaining 33 (49 per cent), uncertainty remains over whether the drugs extend survival or improve quality of life.

The findings raise the possibility that regulatory evidence standards "are failing to incentivise drug development that best meets the needs of patients, clinicians, and healthcare systems."
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications
